Research Progress in TCM Regulating PD-1/PD-L1 Pathway in Malignant Tumors
10.19879/j.cnki.1005-5304.202307406
- VernacularTitle:中医药调控PD-1/PD-L1通路干预恶性肿瘤研究进展
- Author:
Huan JU
1
;
Dan ZHAO
;
Dan LI
;
Ruxi CHEN
;
Bin HAN
Author Information
1. 川北医学院附属医院,四川 南充 637000
- Keywords:
TCM;
immunotherapy;
PD-1/PD-L1 inhibitor;
tumor immunity;
mechanism;
review
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2024;31(8):187-192
- CountryChina
- Language:Chinese
-
Abstract:
Programmed death receptor programmed death ligand 1(PD-1/PD-L1)pathway is an important way to escape from immune surveillance and killing and producing immune escape and is widely expressed in various tumors.By regulating the expression of PD-1/PD-L1 signaling pathway,it can reactivate the anti-tumor immune response and prevent tumor cells from immune escape.PD-1/PD-L1 inhibitors play an important potential in the treatment of tumors,but it has certain limitations.TCM can regulate the body's immune system,improve the tumor microenvironment,and prolong survival.Based on the TCM regulation of PD-1/PD-L1 expression and the application of combining with PD-1/PD-L1 inhibitors in anti-tumor therapy,this study summarized the existing research content and provides reference for the combined application of TCM and immune checkpoint inhibitors in anti-tumor therapy.
